Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | Prognostic factors in mycosis fungoides

Evangelina Papadavid • 14 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases

Evangelina Papadavid, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses the impacts of the COVID-19 pandemic on the management and treatment of patients with cutaneous T-cell lymphoma (CTCL), in particular highlighting the impacts of postponing treatments. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Evangelina Papadavid

2:49
Highlighting unmet needs for CTCL
Evangelina Papadavid et al. • 15 Oct 2021
2:30
Brentuximab vedotin for CTCL
Evangelina Papadavid • 14 Oct 2021
1:25
Future management of CTCL
Evangelina Papadavid • 14 Oct 2021
1:47
Prognostic factors for early-stage CTCL
Evangelina Papadavid • 14 Oct 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals